Table 1.
Baseline patient characteristics
| Characteristic | Value (n=33) |
|---|---|
| Dosing cohort | |
| Continuous dosing | 19 (57.6) |
| Intermittent dosing | 14 (42.4) |
| Age (yr) | 54 (23-69) |
| Male sex | 27 (81.8) |
| Etiology | |
| HBV infection | 26 (78.8) |
| Alcohol | 5 (15.1) |
| Others | 2 (6.1) |
| ECOG performance status | |
| 0 | 10 (30.3) |
| 1 | 23 (69.7) |
| Extrahepatic metastasis | 33 (100) |
| Lung | 27 (81.8) |
| Lymph nodes | 12 (36.4) |
| Peritoneum | 6 (18.2) |
| Bone | 5 (15.2) |
| Previous sorafenib | 33 (100) |
| Previous lines of systemic treatment | 1 (1-7) |
| 1 | 23 (69.7) |
| 2 | 2 (6.1) |
| 3 | 6 (18.2) |
| 5 | 1 (3.0) |
| 7 | 1 (3.0) |
Values are presented as number (%) or median (range).
HBV, hepatitis B virus; ECOG, Eastern Cooperative Oncology Group.